Ster­ling Phar­ma com­pletes ac­qui­si­tion of No­var­tis man­u­fac­tur­ing plant in Ire­land

The UK-based con­tract man­u­fac­tur­er Ster­ling Phar­ma So­lu­tions has com­plet­ed a pur­chase that will give it a man­u­fac­tur­ing pres­ence on the oth­er side of the Irish Sea.

Ster­ling closed its ac­qui­si­tion of an ac­tive phar­ma­ceu­ti­cal in­gre­di­ent (API) plant in the south­ern Irish vil­lage of Ringask­id­dy, Ire­land, that once be­longed to the Swiss phar­ma No­var­tis. The deal, an­nounced in March of last year, will not on­ly give the British CD­MO more ca­pac­i­ty to pro­duce APIs, but al­so in­cludes a sup­ply agree­ment with No­var­tis to con­tin­ue to pro­duce in­gre­di­ents for car­dio­vas­cu­lar, im­munol­o­gy and on­col­o­gy med­i­cines.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER